TRU - Truscreen

[whatsup]

So who is giving more hard earned to this smoke and mirror joint ?

[Digs]

http://www.showroom.co.nz/2015/08/ki...cology-summit/

Maybe this is showing more promise than a lot on here think. Still holding and added a few a while ago

[Misc]

Up 30% in a couple weeks? Speeding Ticket today. I bought in last week. Blue Sky potential, chart looks great. DYOR

[Misc]

Finally.... should get some attention now imo

TRU
15/04/2016 08:30
MKTUPDTE
PRICE SENSITIVE
REL: 0830 HRS TruScreen Limited

MKTUPDTE: TRU: Certification for TruScreen 2nd Generation Device

CERTIFICATION FOR TRUSCREEN 2ND GENERATION DEVICE

CE Mark Certification Opens Up Global Market Opportunities For TruScreen
Cervical Cancer Screening Device

Cancer technology company, TruScreen Limited (NZAX:TRU) advises that its
second generation cervical cancer screening device, known as "TruScreen
Ultra", is now ready for commercial launch in select markets following
receipt of CE Mark certification. This will enable the company to distribute
and sell its TruScreen Ultra device in the European Union and many other
markets that view the CE Mark as an endorsement of compliance, quality &
design of the device's technology & efficacy.

CEO of TruScreen, Mr Martin Dillon, said: "This is a significant step forward
in our commercial plans, allowing us to immediately commence manufacture of
our new device and fill the inventory gap caused last year when all stocks of
the original TruScreen device were sold out."

The TruScreen Ultra device is the culmination of over 2 years of intensive
product development that encapsulates world class medical technology
containing many new & unique features including:

o Massively increased processing capacity and faster processing
o Significantly improved performance
o Wireless handpiece with significantly increased portability
o Rechargeable battery freeing the device from reliance upon continuous
connection to mains power
o Wi-Fi connectivity to PC's, Laptops and Smart Devices
o Internet Browser compatibility
o Graphic User Interface with LCD touch screen.

Recent research reports have estimated the annual global cervical cancer
screening market to be USD $15 billion, and has forecast it to grow to USD
$22 billion by 2020 (1). The granting of the CE mark to TruScreen's new Ultra
device enables the company to immediately target the European Union, India
and other select western markets where TruScreen will be working closely with
both private and public health systems. TruScreen's estimates the potential
annual screening market of the European Union & India to be over USD $329
million and USD $681 million respectively.

The granting of the CE mark of the new device also enables the company to
pursue model upgrade registration with the CFDA in China where the majority
of its commercial activity to date has been centred. The Chinese market is
estimated to have an annual screening value of USD $800 million

TruScreen is the only device in the world that is a CE certified, stand-alone
real time primary screening tool for Cervical Cancer. TruScreen has
successfully combined the use of both optical and electrical tissue
differentiation to create a clinically acceptable level of performance in the
primary screening of cervical cancer.

[GR8DAY]

.....golly gosh, this could be big.....could be huge. Why hasnt the market reacted accordingly? Dont know anything about them but surely this must be very promising?? Anyone care to clarify/comment? whats the history of this co. re losses/ cash burn etc??



Announcement
GENERAL: TRU: TRUSCREEN SELECTED FOR MAJOR CHINESE SCREENING PROGRAMME 08:31a.m.
TRU
31/05/2016 08:30
GENERAL
PRICE SENSITIVE
REL: 0830 HRS TruScreen Limited

GENERAL: TRU: TRUSCREEN SELECTED FOR MAJOR CHINESE SCREENING PROGRAMME

Company Announcement
31 May 2016

TRUSCREEN SELECTED FOR MAJOR CHINESE SCREENING PROGRAMME

o TruScreen to announce FY16 results on 13 June 2016

o NZX approval received to remain on NZAX platform for a further 12 months

Cancer technology company TruScreen Limited (NZAX: TRU) advises that its
technology has been selected for use in a major cervical cancer screening
programme in North China.

The public screening programme is expected to screen 160,000 women over the
next 18 months and is being funded by the Harbin Division of the All China
Federation of Trade Unions ("ACFTU"). The programme is being conducted under
the control of the Provincial Cancer Hospital of Heilongjiang, located in
Harbin City, and involves a number of other leading hospitals in the
Province. TruScreen has satisfactorily completed all medical device
accreditation and verification requirements and completed training of all
medical teams involved.

CEO of TruScreen, Mr Martin Dillon, said: "Providing our technology for use
in fully funded public screening campaigns for cervical cancer in the
enormous Chinese market is an important part of our strategy. ACFTU is the
largest trade union in the world with over 280 million members, and we are
delighted to be affiliated with this programme. We hope to leverage off
this association and extend the use of the TruScreen technology to similar
programmes in other provinces throughout China".

The TruScreen system was selected due to a combination of its real time
nature and its high ability to identify disease, alongside its portability
and independence from laboratory infrastructure. This is different to other
available screening methods and enables the speedy implementation of a large
population based screening program.

TruScreen is the only real time device in the world that is CE certified for
the stand-alone primary screening of cervical cancer. It successfully
combines the use of both optical and electrical tissue differentiation to
create a clinically acceptable level of performance as a primary screening
tool.

TruScreen to Announce FY16 Results on 13 June 2016; Approval to remain on
NZAX Platform

TruScreen advises that it expects to announce its full year results for the
year ended 31 March 2016, by 14 June 2016. In addition, the company has
confirmed that it has received notice that it will not need to migrate it's
listing to the NXT Market platform operated by NZX Limited during the next 12
months.

ENDS

[heisenberg]

This company is nothing but a speculative play to me. The product itself seems to have similar effectiveness at detecting cervical cancer as a well performed Pap smear. I don't see it as having much use in places where a laboratory is readily available.

Disc: hold none

[GR8DAY]

.......from what Im reading that's exactly what it's all about ie especially (but not only) for screening women in places where labs are not accessible. Im guessing this could apply to many millions of women..... if not billions?

[Lewylewylewy]

I did some research into this product... the issue seems to be that although the product is awesome because it picks out things the existing solution can't, it can only be used in conjunction with the existing solution (which picks out things it can miss). And the existing solution is deemed adequate for most common instances.

It would be great if this product was used in all cases as it significantly improves detection rates. I however, decided not to invest because of my lack of faith in hospital administration's % doctors quality of care. I believe that it's a (wrongly) hard sell.

Hope I'm wrong and good luck to anyone who does invest. I may join you later when I have some spare cash for an ethical investment.

[GR8DAY]

...thanks Lewy for that. It must have some serious merits tho to be selected for this large Chinese study involving 160,000 woman. They wouldnt have gone into this lightly. Im liking what ive read thus far and as you rightly say it's a good ethical business as well........always keen to see this sort of thing do well. 18mnths is not long to wait either for results from the study.

[GR8DAY]

.........hmmmmmm, gaining some more traction here? Good foothold now into Europe. (re: todays announcement)